Semaglutide
A GLP-1 receptor agonist medication; approved for diabetes (Ozempic), weight loss (Wegovy), and cardiovascular outcomes (SELECT trial); dosed once weekly at varying strengths
As defined in Ozempic & Mounjaro: Same Shot. Opposite Results.
Other definitions
A GLP-1 agonist peptide (brand names Ozempic, Wegovy) that enhances insulin secretion and suppresses appetite; widely used for weight loss and Type 2 diabetes
Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD
Where it comes up · 4
- Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD4 claims
- Ozempic & Mounjaro: Same Shot. Opposite Results.3 claims
- Doctor Reviews NAD+ vs Peptides - Which Does MORE?2 claims
- Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]1 claim
Most important claims · 10 of 10Search all claims for “Semaglutide” →
- In the FLOW trial, semaglutide reduced risk of clinically important kidney outcomes and reduced cardiovascular death in people with type 2 diabetes and chronic kidney disease.Ozempic & Mounjaro: Same Shot. Opposite Results.
- Deterioration Phenotype Four is advanced diabetes with microvascular vulnerability, especially eye disease risk; in SUSTAIN 6 study, semaglutide was associated with higher rates of diabetic retinopathy complications versus placebo, often discussed in the context of rapid glucose improvement in people with preexisting retinopathy risk.Ozempic & Mounjaro: Same Shot. Opposite Results.
- Semaglutide and tirzepatide achieve the same goals and differ mainly in novel intellectual property strategies, so from an investment perspective they are largely interchangeable.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
- In the STEP 1 trial, adults with overweight or obesity without diabetes treated with once-weekly semaglutide at 2.4 mg led to approximately 14.9% mean weight loss at 68 weeks compared to approximately 2.4% with placebo alongside lifestyle interventions, GI side effects were common and discontinuation due to GI events was higher with semaglutide, and STEP 1 trial showed improvements across a range of cardiometabolic markers.Ozempic & Mounjaro: Same Shot. Opposite Results.
- GLP-1 receptor agonists like semaglutide should be prescribed at one-fifth to one-tenth of the maximum dose in most obese patients rather than at approved doses, because lower doses serve as 'training wheels' that facilitate lifestyle habit formation (diet, exercise, sleep) without suppressing appetite so much that patients cannot learn sustainable behaviors.Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD
- For approximately 98% of non-diabetic individuals with obesity and mild metabolic syndrome, semaglutide (GLP-1) is the most potent medication needed; more powerful GLP-1/GIP combination agonists (like tirzepatide/Mounjaro) and triple agonists are unnecessary and create an 'arms race' of escalation driven by pharmaceutical competition rather than clinical need.Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD
- Wellness spas that claim peptides are for human use are likely lying, except for semaglutide, tirzepatide, PT-141, sermorelin, oxytocin, and maybe a few others; these facilities operate in murky regulatory waters and know it.Doctor Reviews NAD+ vs Peptides - Which Does MORE?
- There are many peptides with various functions, including tessamorin, ibomorin, semaglutide, tirzepatide, BPC-157, matrixyl, melanotan, and epitalon, each targeting different outcomes like muscle growth, strength, weight loss, emotional bonding, sleep, or skin tanning.Doctor Reviews NAD+ vs Peptides - Which Does MORE?
- Terzapatide (Mounjaro) is a GLP-1/GIP dual agonist that combines effects of semaglutide (GLP-1 only) with additional GIP receptor activation, providing more potent glucose lowering and weight loss than GLP-1 monotherapy.Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD
- Liraglutide (another GLP-1 receptor agonist) is a formulation Gillette particularly favors and is expected to become generic soon, making it more accessible than semaglutide for patients.Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD